Current evidence of neurological features, diagnosis, and neuropathogenesis associated with COVID-19

Puccioni-Sohler, Márzia; Poton, André Rodrigues; Franklin, Milena; Silva, Samya Jezine da; Brindeiro, Rodrigo de Moraes; Tanuri, Amílcar

doi:10.1590/0037-8682-0477-2020

Cited by 22 publications

(31 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to previous literatures, SARS-CoV-2 infection can cause complications via direct invasion and immune disturbance through hematogenous or transsynaptic propagation (Figure 2) (Haddadi and Asadian, 2020;Puccioni-Sohler et al, 2020). SARS-CoV-2 is regarded as neurotropic virus.…”

Section: Mechanism Of Sars-cov-2 Infectionmentioning

confidence: 96%

“…Neurological manifestations could occur in the central nervous system (CNS), peripheral nervous system (PNS), and relative skeletal muscles (Kutlubaev, 2020 ; Mao et al, 2020 ; Puccioni-Sohler et al, 2020 ). A systematic review about 290 patients revealed that 91% of patients with neurological discomfort present with CNS symptoms, while only PNS symptoms account for 9% (Ibrahim, 2020 ).…”

Section: Neurological Complications Of Covid-19mentioning

confidence: 99%

“…It is known that viruses and immune factors enter the developing human brain through a weakened blood–brain barrier and induce neural impairments (da et al, 2020 ). Although not all cases test positive for SARS-CoV-2 in the CSF, signs of nervous system infection or impairment should arouse clinicians' attention to probable neurological complications of COVID-19 (Puccioni-Sohler et al, 2020 ).…”

Section: Neurological Complications Of Covid-19mentioning

confidence: 99%

“…The prevalence of smell and taste dysfunctions decreases in older patients (Agyeman et al, 2020 ), and female patients are more prone to smell disturbance (Meng et al, 2020 ). Furthermore, about 12% of the COVID-19 patients develop only anosmia as initial symptom (Puccioni-Sohler et al, 2020 ). Eight cases developed sudden and complete loss of smell without respiratory symptoms (Gilani et al, 2020 ).…”

Section: Neurological Complications Of Covid-19mentioning

confidence: 99%

See 3 more Smart Citations

Severe Acute Respiratory Syndrome Coronavirus 2-Induced Neurological Complications

2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Our review aims to highlight the neurological complications of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the available treatments according to the existing literature, discussing the underlying mechanisms. Since the end of 2019, SARS-CoV-2 has induced a worldwide pandemic that has threatened numerous lives. Fever, dry cough, and respiratory symptoms are typical manifestations of COVID-19. Recently, several neurological complications of the central and peripheral nervous systems following SARS-CoV-2 infection have gained clinicians' attention. Encephalopathy, stroke, encephalitis/meningitis, Guillain–Barré syndrome, and multiple sclerosis are considered probable neurological signs of COVID-19. The virus may invade the nervous system directly or induce a massive immune inflammatory response via a “cytokine storm.” Specific antiviral drugs are still under study. To date, immunomodulatory therapies and supportive treatment are the predominant strategies. In order to improve the management of COVID-19 patients, it is crucial to monitor the onset of new neurological complications and to explore drugs/vaccines targeted against SARS-CoV-2 infection.

show abstract

Section: Mechanism Of Sars-cov-2 Infectionmentioning

confidence: 96%

Section: Neurological Complications Of Covid-19mentioning

confidence: 99%

Section: Neurological Complications Of Covid-19mentioning

confidence: 99%

Section: Neurological Complications Of Covid-19mentioning

confidence: 99%

See 2 more Smart Citations

Severe Acute Respiratory Syndrome Coronavirus 2-Induced Neurological Complications

2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…Intrathecal SARS-CoV-2 IgG and specific IgM in CSF have been found in RT-PCR assay-negative COVID-19 cases. These markers may be promising for the diagnosis of COVID-19 in cases with CNS symptoms ( 23 ). Calculation of the IgG antibody index (AI) is based on Reiber's method ( 24 ).…”

Section: Discussionmentioning

confidence: 99%

Case Report: Identification of SARS-CoV-2 in Cerebrospinal Fluid by Ultrahigh-Depth Sequencing in a Patient With Coronavirus Disease 2019 and Neurological Dysfunction

Pan

Lü

et al. 2021

Front. Med.

View full text Add to dashboard Cite

We reported that the complete genome sequence of SARS-Coronavirus-2 (SARS-CoV-2) was obtained from a cerebrospinal fluid (CSF) sample by ultrahigh-depth sequencing. Fourteen days after onset, seizures, maxillofacial convulsions, intractable hiccups and a significant increase in intracranial pressure developed in an adult coronavirus disease 2019 patient. The complete genome sequence of SARS-CoV-2 obtained from the cerebrospinal fluid indicates that SARS-CoV-2 can invade the central nervous system. In future, along with nervous system assessment, the pathogen genome detection and other indicators are needed for studying possible nervous system infection of SARS-CoV-2.

show abstract

Miller Fisher syndrome associated with COVID-19: an up-to-date systematic review

Shen

et al. 2021

Environ Sci Pollut Res

View full text Add to dashboard Cite

Recently, during the pandemic infection of the novel SARS-CoV-2, some cases of Miller Fisher syndrome (MFS) have been reported. We want to summarize the main features of patients with MFS and COVID-19. A PubMed search was performed on 8 October to identify references reporting cases with MFS associated with COVID-19 from the first report of COVID-19 to 8 October 2020 using the following keywords: “Miller Fisher syndrome” AND “COVID-19” OR “SARS-CoV-2”. A systematic review from the first report of coronavirus disease 2019 (COVID-19) to 8 October 2020 revealed 7 cases with Miller Fisher syndrome (MFS) associated with COVID-19. The 7 cases came from 5 countries but most of these patients were from Europe (85.7%), especially Spain. There are 5 cases of MFS diagnosed after the laboratory confirmation of SARS-CoV-2 infection. The mean onset time of MFS-associated neurological symptoms was 14.75 days after the diagnosis of COVID-19. However, the two remaining cases presented initially with MFS-associated neurological symptoms followed by the diagnosis of COVID-19. The most common symptoms of COVID-19-associated MFS were perioral paresthesias (57.1%), ataxia (57.1%), blurred vision (42.9), ophthalmoplegia (42.9), and generalized areflexia (42.9). However, more cohort and case-control studies are required to establish the epidemiological linkage.

show abstract

Current evidence of neurological features, diagnosis, and neuropathogenesis associated with COVID-19

Cited by 22 publications

References 41 publications

Severe Acute Respiratory Syndrome Coronavirus 2-Induced Neurological Complications

Severe Acute Respiratory Syndrome Coronavirus 2-Induced Neurological Complications

Case Report: Identification of SARS-CoV-2 in Cerebrospinal Fluid by Ultrahigh-Depth Sequencing in a Patient With Coronavirus Disease 2019 and Neurological Dysfunction

Miller Fisher syndrome associated with COVID-19: an up-to-date systematic review

Contact Info

Product

Resources

About